Apotex Health

Apotex Health (Ticker: APTX CN) manufactures generic medicines and consumer health products for customers across international markets. Its product range includes more than 800 pharmaceutical and consumer health products. The company serves customers in about 70 countries and employs more than 6,000 people worldwide. SK Capital Partners owned Apotex before the IPO and was expected to remain its majority shareholder afterward. The offering included 35.42 million newly issued primary shares and 18.75 million secondary shares, with a 15% greenshoe facility.

The scheduled listing date on Toronto Stock Exchange was June 10, 2026. The offering comprises 54,170,000 shares at a confirmed price of CAD 24.00 per share, compared with an indicative range of CAD 20.00–24.00. At the confirmed offer price, the base offering represents CAD 1.30 billion, approximately $919.63 million in gross proceeds, excluding any unexercised over-allotment.

BMO Capital Markets, Jefferies Securities, RBC Capital Markets, Scotiabank and TD Securities managed the IPO.